Cellino Biotech, a fairly new company in the biotech landscape. Still, the firm is making waves in the biotech world right now because it promises to take stem cell therapies to a whole new level.
What does it want to do?
It wants to use artificial intelligence to improve the scale of stem cell therapy production.
Its proposed advancements for stem cell manufacturing is taking the biotech sector by storm and it is recently the talk of the town due to its new updates.
The Firm Has Raised $80 Million In Funding
Cellino Biotech has announced its completion of Series A, in which an investment of around $80 million will be led by Bayer AG, 8VC, and Humboldt Fund. In addition to this, multiple new investors are willing to join the existing chain of investors. These include Felicis Ventures. Moreover, around $96 million has also increased through private finance proceedings.
The overall motive of Cellino is to make stem cell therapy more accessible to prevent, diagnose and treat diseases. It also aims to enhance the manufacturing and handling procedures to overcome limitations. Bayer, the primary investor, has said that they are influenced by the unique approach of Cellino to make stem cell therapy accessible and cut off the manufacturing cost and expenses.
Bayer said they believe in providing long-term solutions to the most significant challenges faced during stem cell therapy manufacturing. Moreover, Bayer also said that their ambition perfectly correlates with Cellino’s approach. According to Bayer, intelligence-driven technology is the following critical reflection in future manufacturing.
Guided and Driven By Software
Cellino aims to build an AI-driven future when it comes to regenerative medicine. In addition to this, they aim to work through a software-driven closed-loop platform that helps industrialize stem cell therapy.
This can be done by involving principles of multiple subjects such as biology and physics in manufacturing.
The involvement of Series A financing will indeed be much helpful for Cellino as it will expand Cellino’s software. In addition to this, it will bring improvements in hardware capabilities and end-to-end manufacturing of both autologous and allogeneic stem cell therapy.
Moreover, Cellino intends to work with multiple organizations such as NIH. At NIH, doctors are working on the first autologous induced pluripotent stem cell therapy, which will involve clinical trials at the early GMP stage.
The next-generation processes led by Cellino involve high-speed laser editing, label-free imaging, automated cell programming, and many more.
Significant Investments Taking Place in Cell Therapy During the Pandemic
One trend that we are seeing at GeekInsider is the larger appetite for stem cell therapy companies during the pandemic. More companies have made advancements in this sector and are making progress in each and every aspect of the process. We have talked about companies ranging from Invitae to Pacific Biosciences of California, Inc and more.